CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their price targets and ratings for several US-listed companies. Keybanc raised Invitation Homes' target from $35 to $38, maintaining an Overweight rating. Needham increased Simply Good Foods' target from $42 to $45 with a Buy rating. Raymond James raised Tradeweb Markets' target from $94 to $102, maintaining an Outperform rating. Stifel upgraded CACI International from Hold to Buy, raising the target from $365 to $380. Morgan Stanley raised Cytokinetics' target from $60 to $90 but downgraded it to Equal-Weight. Jefferies raised Okta's target from $85 to $95 but downgraded it to Hold. HC Wainwright cut Viracta Therapeutics' target from $10 to $4 but kept a Buy rating. Morgan Stanley cut CI&T's target from $6 to $5.5 and downgraded it to Equal-Weight. Baird raised Rexford Industrial Realty's target from $53 to $61 but downgraded it to Neutral. Needham cut Mobileye Global's target from $43 to $36 but maintained a Buy rating.
January 05, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel upgraded CACI International from Hold to Buy and raised the price target from $365 to $380.
The upgrade to Buy and the higher price target suggest strong analyst confidence in CACI International, which could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Keybanc raised Invitation Homes' price target from $35 to $38 and maintained an Overweight rating.
The increase in price target and the maintenance of an Overweight rating suggest a positive outlook, which could lead to a short-term rise in INVH's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Needham boosted Simply Good Foods' price target from $42 to $45 and maintained a Buy rating.
The raised price target and continued Buy rating indicate a positive sentiment from analysts, which could contribute to upward momentum for SMPL's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Raymond James raised Tradeweb Markets' price target from $94 to $102 and maintained an Outperform rating.
The increased price target and Outperform rating reflect analyst confidence in Tradeweb Markets' potential, likely leading to a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Morgan Stanley raised Cytokinetics' price target from $60 to $90 but downgraded the stock to Equal-Weight.
The higher price target is positive, but the downgrade to Equal-Weight introduces uncertainty, likely resulting in a neutral short-term impact on the stock.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Jefferies raised Okta's price target from $85 to $95 but downgraded the stock from Buy to Hold.
The increased price target is offset by the downgrade to Hold, suggesting a balanced view that may not significantly move the stock in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Baird raised Rexford Industrial Realty's price target from $53 to $61 but downgraded the stock to Neutral.
The increase in price target is a positive sign, but the downgrade to Neutral indicates a lack of strong conviction, likely leading to a neutral impact on the stock.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Morgan Stanley cut CI&T's price target from $6 to $5.5 and downgraded the stock to Equal-Weight.
The reduced price target and downgrade to Equal-Weight suggest a less optimistic outlook, which could negatively affect CI&T's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Needham cut Mobileye Global's price target from $43 to $36 but maintained a Buy rating.
The lowered price target could dampen investor sentiment, but the maintained Buy rating may provide some support, resulting in a potentially mixed short-term impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
NEGATIVE IMPACT
HC Wainwright cut Viracta Therapeutics' price target from $10 to $4 but maintained a Buy rating.
The significant cut in price target could overshadow the maintained Buy rating, potentially leading to a negative short-term impact on VIRX's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80